Atzumi Shortage Update: What Patients Need to Know in 2026

If you've been prescribed Atzumi (dihydroergotamine nasal powder) and you're having trouble getting it filled, you may be wondering: is there an official shortage? And what can you actually do about it? Here's the current status in 2026.

Is Atzumi in an Official FDA Drug Shortage?

As of 2026, Atzumi is NOT listed on the FDA's official drug shortage database. The FDA defines a drug shortage as a situation where the supply of a drug is inadequate to meet demand due to manufacturing or quality problems. That is not what's happening with Atzumi. Satsuma Pharmaceuticals, the manufacturer, continues to produce and distribute Atzumi.

The access challenges patients are experiencing are structural — they stem from the realities of launching a new, high-cost, brand-name specialty drug in the U.S. healthcare system — not from a manufacturing problem.

Why Are Patients Having Trouble Finding Atzumi?

Atzumi received FDA approval on April 30, 2025 — making it one of the newest prescription migraine treatments available. In the months since launch, several access barriers have emerged:

Distribution lag: New drug supply chains take time to scale. Pharmacies don't automatically stock newly-approved branded specialty medications.

Insurance prior authorization: Major pharmacy benefit managers added Atzumi to prior authorization requirements shortly after its June 2025 commercial launch. This delays coverage and access.

High cash price: Estimated at $900–$1,200+ for a carton of 8 devices, Atzumi's price makes pharmacies hesitant to stock it without confirmed prescriptions.

Specialty pharmacy routing: Some insurance plans direct Atzumi to specialty pharmacies rather than standard retail, limiting where patients can fill it.

What Is the Background on Dihydroergotamine Access?

Dihydroergotamine (DHE) itself has a long history of access challenges. The original brand D.H.E. 45 injection was discontinued years ago, though generic injectable DHE remains available. Migranal (DHE nasal spray) has faced intermittent availability issues as a legacy product. Trudhesa, the next-generation DHE nasal spray approved in 2021, helped reestablish DHE access for intranasal delivery. Atzumi represents the latest evolution — a powder formulation with improved pharmacokinetics.

The pattern of access challenges for DHE-class medications is well established. Patients who rely on DHE have navigated these hurdles before — but Atzumi's newness creates an additional layer of initial friction.

What Can Patients Do in 2026?

Here are the most effective steps patients can take right now:

Use medfinder to check local pharmacy availability: medfinder.com calls pharmacies near you to find which ones can fill your Atzumi prescription. This is faster and more reliable than calling pharmacies yourself.

Ask your doctor to expedite prior authorization: The PA process is often the biggest bottleneck. Your prescriber should include documentation of previous migraine treatments to support the PA.

Contact Satsuma's patient support: Call 1-888-273-2480 or visit satsumarx.com for help with pharmacy access and coverage questions.

Ask about a bridge prescription: Generic DHE nasal spray or a triptan can bridge the gap while your Atzumi access is sorted out.

Explore specialty pharmacy options: If your insurance routes Atzumi through specialty channels, contact your insurer for in-network specialty pharmacy options that can deliver directly to your home.

Will Access Improve in 2026?

The trajectory is positive. As more neurologists and headache specialists become familiar with Atzumi and prescriptions increase, pharmacies will stock it more routinely. Insurance formulary coverage should also expand and stabilize. The structural access barriers of a new drug launch typically ease within 12–18 months of market entry as the distribution network matures.

Bottom Line

Atzumi is not in an FDA shortage — the drug is being manufactured and distributed. The challenge is navigating the early-launch access barriers of a new specialty drug. Use medfinder to find pharmacies with Atzumi in stock, push your insurer on the PA process, and check out our list of alternatives to Atzumi if you need a bridge option while you wait.